US-based company is developing next-generation sequencers, using AI models in the Republic to speed up diagnostics and lower ...

SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq™ i100 Series of sequencing systems, ...

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families. Through a ...

The company's multi-year strategy involves the rollout of new products and upgrades to existing ones that further strengthen its position.

Massey Genome Service (MGS) has invested in two Illumina MiSeq™ instruments. We offer Illumina MiSeq™ sequencing with the following applications: Send the Massey Genome Service (MSG) an email about ...

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced MiSeq™, a low-cost personal sequencing system that provides individual researchers a platform with rapid turnaround time, ...

Illumina is suing Element Biosciences, with the sequencing giant accusing its smaller rival of infringing on five of its patents covering flow cell and imaging technologies used in automated genetic ...

Illumina Inc. (NASDAQ:ILMN) has agreed to pay $9.8 million to resolve allegations it knowingly sold genomic sequencing systems with cybersecurity vulnerabilities to several U.S. government agencies.

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc.

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families. Through a ...